289P Manageable longer-term safety with the highly-selective colony stimulating factor-1 receptor (CSF-1R) inhibitor pimicotinib in patients with tenosynovial giant cell tumor (TGCT) in the global MANEUVER trial
Abstract
Pimicotinib (pimi) is an investigational, potent, small molecule CSF-1R inhibitor for TGCT. In the phase 3 MANEUVER trial, pimi met its primary endpoint and provided robust tumor responses, clinically significant symptomatic and functional improvements, and manageable safety profile. Here, we report the incidence and timing of key adverse events (AEs) of clinical interest (AECIs) in MANEUVER.
Fields of Study & Subjects
Musculoskeletal synovial abnormalities and treatments
Sarcoma Diagnosis and Treatment
Rheumatoid Arthritis Research and Therapies
Publication details
- Journal / source
- ESMO rare cancers.
- Volume
- 5
- Pages
- 100214–100214
- Publication date
- 1 March 2026
- Language
- EN